首页> 外文OA文献 >Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis

【2h】

Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis

机译：比较疾病改良药物治疗复发缓解型多发性硬化症一线治疗的成本效益

页面导航

著录项
相似文献
相关主题

著录项

作者
Lawrence D. Goldberg; Mba Natalie; C. Edwards; Msc Contessa Fincher; Quan V. Doan; Mshs Ahmad Al-sabbagh; Dennis M. Meletiche; J Manag; Care Pharm;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. [J] . Goldberg LD, Edwards NC, Fincher C Journal of managed care pharmacy : . 2009,第7期

机译：比较疾病缓解药物在一线治疗复发缓解型多发性硬化症中的成本效益。
2. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. [J] . Gani R, Giovannoni G, Bates D PharmacoEconomics . 2008,第7期

机译：在英国，那他珠单抗（Tysabri）与其他疾病缓解疗法相比对高活性复发缓解型多发性硬化症患者的成本效益分析。
3. First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence [J] . Ferraro Diana, Camera Valentina, Baldi Eleonora, Current medical research and opinion . 2018,第10期

机译：一线疾病改性药物复发 - 延长多发性硬化症：一种对持久性的意大利现实生活中的研究
4. Microstructural Modulations in the Hippocampus Allow to Characterizing Relapsing-Remitting Versus Primary Progressive Multiple Sclerosis [C] . Lorenza Brusini, Ilaria Boscolo Galazzo, Muge Akinci, International Workshop on Brain-Lesion;Medical Image Computing and Computer Assisted Intervention Conference . 2020

机译：海马中的微观结构调制允许表征复发 - 延长与初级进步多发性硬化
5. Cost-Effectiveness of Oral Agents in Relapsing-Remitting Multiple Sclerosis Compared to Interferon-Based Therapy in Saudi Arabia [D] . Alskaabi, May. 2017

机译：沙特阿拉伯口服药物在复发缓解型多发性硬化症中的成本效果与基于干扰素的疗法相比
6. Disease-Modifying Drugs Reduce Cortical Lesion Accumulation and Atrophy Progression in Relapsing-Remitting Multiple Sclerosis: Results from a 48-Month Extension Study [O] . Francesca Rinaldi, Paola Perini, Matteo Atzori, 2015

机译：疾病改良药物可减少复发性多发性硬化症的皮质病变累积和萎缩进程：48个月延长研究的结果
7. Cost-Effectiveness Analysis of Peginterferon Beta-1a Vs. First-Line Injectable Disease-Modifying Therapies For The Treatment of Relapsing-Remitting Multiple Sclerosis In Spain [O] . L Ruiz, H Toro-Diaz, C Cele, 2017

机译：Peginterferon Beta-1a的成本效益分析一线可注射疾病 - 改性治疗西班牙复发复杂多发性硬化的疗法

Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis

著录项

相似文献

相关主题

期刊订阅